Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion.

IGF binding proteins (IGFBPs) modulate IGF cellular bioavailability and may directly regulate tumor growth and invasion. We have previously shown that IGFBP-2 binds and localizes IGF-I to the pericellular matrix and have provided some evidence suggesting that the heparin binding domain (HBD) or the arginine-glycine-aspartic acid (RGD) integrin binding motif may be involved in these interactions. However, the precise mechanisms involved remain to be elucidated. We therefore mutated the HBD or RGD sequence of IGFBP-2 and investigated consequent effects on extracellular matrix (ECM) binding, IGF-induced proliferation, and migration of neuroblastoma cells. IGFBP-2 and its arginine-glycine-glutamic acid (RGE) mutant similarly bound ECM components, whereas binding of mutant HBD-IGFBP-2 to each of the ECM substrates was markedly reduced by 70-80% (P < 0.05). IGF-I (100 ng/ml) increased incorporation of 3H-thymidine in neuroblastoma SK-N-SHEP cells by approximately 30%, an effect blunted by exogenously added native or either mutant IGFBP-2. Overexpression of IGFBP-2 and its RGE mutant potently promoted SHEP cell proliferation (5-fold), whereas SHEP cell proliferation was negligible when HBD-IGFBP-2 was overexpressed. Addition or overexpression of IGFBP-2 and its RGE mutant potently (P < 0.05) enhanced SHEP cell migration/invasion through the ECM. However, overexpression of the HBD-IGFBP-2 mutant potently inhibited (50-60%) SHEP cell invasion through ECM. Thus, IGFBP-2, which binds to the ECM, enhances proliferation and metastatic behavior of neuroblastoma cells, functions that directly or indirectly use the HBD but not the integrin binding sequence. Our novel findings thus point to a key role for the HBD of IGFBP-2 in the control and regulation of neuroblastoma growth and invasion.

Polymorphisms in the Il12b gene affect structure and expression of IL-12 in NOD and other autoimmune-prone mouse strains.

Interleukin (Il)-12 is a heterodimeric cytokine composed of 35 and 40 kD chains that plays a key role in the induction of Th1 cells, a T cell subset involved in many autoimmune diseases. We report here the cDNA sequence encoding the IL-12 p40 subunit from the autoimmune-prone non-obese diabetic (NOD) mouse, which spontaneously develops type 1 diabetes. Compared with the C57BL/6 sequence, there are two base changes that lead to amino acid replacements. Other autoimmune-prone strains, but not the diabetes-resistant NOR strain, share the same allele as NOD. We found both trans- and cis- allele-dependent effects on levels of basal and induced IL-12p40 expression. Furthermore, we show that one of these changes results in a structural change in the p40 molecule, as evidenced by the failure of a monoclonal antibody to bind NOD IL-12. These findings have implications for the predisposition to autoimmune responses in NOD and other autoimmune-prone mouse strains.

Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele.

Type 1 diabetes (T1D; or insulin-dependent diabetes mellitus, IDDM) is an autoimmune disease with both genetic and environmental components. In addition to the human leukocyte antigen (HLA) complex, the single major genetic contributor of susceptibility, an unknown number of other unidentified genes are required to mediate disease. Although many loci conferring susceptibility to T1D have been mapped, their identification has proven problematic due to the complex nature of this disease. Our strategy for finding T1D susceptibility genes has been to test for human homologues of loci implicated in diabetes-prone NOD (non-obese diabetic) mice, together with application of biologically relevant stratification methods. We report here a new susceptibility locus, IDDM18, located near the interleukin-12 (IL-12)p40 gene, IL12B. Significant bias in transmission of IL12B alleles was observed in affected sibpairs and was confirmed in an independent cohort of simplex families. A single base change in the 3' UTR showed strong linkage disequilibrium with the T1D susceptibility locus. The IL12B 3' UTR alleles showed different levels of expression in cell lines. Variation in IL-12p40 production may influence T-cell responses crucial for either mediating or protecting against this and other autoimmune diseases.

Evidence for two distinct classes of high affinity growth hormone binding proteins in pregnant rat serum.

These studies have established the presence of two major classes of high affinity growth hormone binding proteins in pregnant rat serum, designated GHBPa and GHBPb, with apparent native Mr of 257 K and 98 K respectively. GHBPa, which has not been identified previously, exhibits a binding affinity (2-5 nM(-1)) that is up to 20-fold higher than GHBPb (0.2-0.8 nM(-1)) and is the least abundant form, being approximately 15-20% of total serum GH-binding capacity. Western immunoblot analysis revealed that each GHBP is composed of several immunoreactive proteins which were reactive with carboxy-terminal (RB1615) and/or N-terminal (MAb263) domain antibodies, suggesting the presence of GHBPs with and without the hydrophilic tail. Of importance is that GHBPa exhibited significantly higher Mr (78-182 K, +DTT) than that predicted by GHBP cloning, suggesting that they may be covalently bound to other non-GH-binding proteins or may be distinct entities. GHBPb, on the other hand, was composed of smaller Mr (43/48 K, +DTT) "hydrophilic" tail-containing proteins, some of which were disulphide linked to a larger complex of approximately 110 K. These novel findings challenge the current view of the mechanism for generation of the rat serum GHBP and raise the intriguing possibility that the two classes of GHBP may play distinct and important roles in GH physiology.

Guinea pig serum contains a specific high affinity growth hormone-binding protein with novel ligand specificity.

Previous workers have suggested that guinea pig serum does not contain a GH-binding protein (GHBP) or that it is defective. The current studies, however, have identified and characterized the presence of GH-binding activity in guinea pig serum using gel chromatography to separate bound and free hormone. The detection of GH-binding activity is critically reliant on the type of radioligand used to measure binding. Clear identification of GH-binding activity was demonstrated with [125I]ovine GH (oGH), but specific binding could not be measured with [125I]human GH. The novel specificity was also shared by guinea pig liver membrane GH receptor (GHR) and cytosol GHBP, suggesting structural similarity in the GH-binding domain between the GHR and soluble GHBPs. The binding of oGH was dependent on serum concentration (5 microl serum produced 16.03 +/- 0.5% specific binding; mean +/- SEM; n = 11) and incubation time (equilibrium was reached by approximately 6 h at 21 C) and was completely reversible (t(1/2), approximately 2 h). Scatchard analysis revealed linear plots with an affinity constant (Ka) of 0.59 +/- 0.09 x 10(9) M(-1) and a capacity of 23,181 +/- 4,474 fmol/ml serum. Similar association constants were obtained for liver membrane GHR (0.79 +/- 0.22 x 10(9) M(-1)) and cytosol GHBPs (0.99 +/- 0.15 x 10(9) M(-1)), but the capacity, when expressed as femtomoles per g tissue, was significantly increased (4-fold) in cytosol (4,303 +/- 505) over that in membranes (1,071 +/- 257). There was no sex difference in Ka or level of GHBP in guinea pig serum. Surprisingly, the level of GH-binding activity was very low to undetectable in pregnant guinea pig serum. Characterization of the native structure of guinea pig GHBPs has indicated the presence of several proteins that are structurally distinct. Although the distribution of GH-binding activity covered a large Mr range (approximately 70-350 kDa) the major form of the circulating GHBP identified by gel chromatography had an apparent native Mr of 150-170 kDa. Partially purified GHBP (approximate Mr, 170 kDa) was covalently cross-linked to [125I]oGH and subjected to nonreducing SDS-PAGE. Specific GHBP complexes of 158 and 85 kDa were detected, suggesting that the partially purified GHBP complex may be composed of a smaller GHBP associated noncovalently with a non-GH-binding protein. "Pore limit" native PAGE (cathodic and anodic) revealed the presence of specific GHBPs of 363, 158, 74, and 55 kDa, which cross-hybridized with the rat liver membrane GHR monoclonal antibody mAb 263 but not with the rat serum GHBP-specific mAb 4.3. Interestingly, although GH binding was undetectable in pregnant guinea pig serum, Western immunoblot analysis with mAb 263 demonstrated the presence of a major immunoreactive GHBP band of 105 kDa in addition to 158- and 55-kDa GHBPs. The data indicate that the GHBPs are immunologically related to the rat membrane GHR, but provide no evidence to support the presence of a hydrophilic tail sequence homologous to that in the rat GHBP. These studies have identified in guinea pig serum GHBPs that exhibit novel ligand specificity, structural heterogeneity, and an immunological relationship to the rat liver membrane GHR. The identification of serum GHBP and the novel ligand specificity, which is also expressed by the liver membrane GHR, argue against the view that the guinea pig has a defective GHBP.

Growth hormone receptor/binding protein: physiology and function.

Soluble truncated forms of the growth hormone receptor (GHR) are present in the circulation of many species and are also produced by many tissues/cell types. The major high-affinity forms of these GH-binding proteins (GHBP) are derived by alternative splicing of GHR mRNA in rodents, but probably by proteolytic cleavage in other species. Questions still remain with respect to the origins, native molecular form(s), physiology, and function of the GHBPs, however. The observation that GH induces dimerization of the soluble GHBP and membrane GHR, and that dimerization of GHR appears to be critical for GH bioactivity suggests that the presentation of GH to target cells, in an unbound form or as a monomeric or dimeric complex with GHBP, may have significant implications for the ability of GH to activate specific postreceptor signaling pathways (tyrosine kinase, protein kinase C, G-protein pathways) known to be utilized by GH for its diverse biological effects. This minireview addresses some of these aspects and highlights several new questions which have arisen as a result of recent advances in our understanding of the structure, function, and signaling mechanisms of the membrane bound GHR.

Developmental expression of the growth hormone receptor gene in rabbit tissues.

Total RNA from several adult (6-18-month-old) rabbit tissues was characterized using an oligonucleotide probe derived from the extracellular domain of the nucleotide sequence of the rabbit growth hormone receptor (GH-R) cDNA. Multiple GH-R mRNA species of approximately 4.6, approximately 3.3, 2.1 and approximately 1.4 kb were detected. The major 4.6 kb transcript was detectable in all tissues examined but with quite marked abundance differences. The highest level of expression was observed in liver followed closely by muscle. A qualitative assessment of insulin-like growth factor I (IGF-I) mRNA abundance was made in these same tissues. The data showed that the tissue abundance of GH-R mRNA was not necessarily parallel to that of IGF-I mRNA. The ontogeny of GH-R mRNA was studied in rabbit liver, muscle, heart and kidney. Low levels of GH-R mRNA were detectable in all fetal tissues studied except kidney which showed relatively high levels, suggesting that GH may play an important role in early kidney development. The overall developmental pattern of GH-R mRNA was similar in heart, muscle and liver, being low in fetal and early neonatal (day 3) periods and reaching maximal levels between 2 and 6 months. However, in kidney the pattern contrasted markedly. Relatively high levels of GH-R mRNA were observed in fetal and early neonatal (day 3) kidney with little change throughout development. The developmental pattern of IGF-I gene expression was not necessarily co-ordinately regulated with the ontogenic pattern of GH-R gene expression.(ABSTRACT TRUNCATED AT 250 WORDS)

Serum binding proteins for growth hormone: origins, regulation of gene expression and possible roles.

The above discussion highlights the heterogeneity of the family of GH receptors/GHBPs and their mRNAs. Considerable uncertainty still exists as to the interrelationships between the various forms, the specific mechanisms for their generation and their possible significance in terms of modulating GH action and receptor function. Collectively, the regulatory data indicate that while the mRNAs encoding the membrane and soluble GH receptors/GHBPs in the rat are expressed by the same broad distribution of tissues, they can be differentially regulated. Such regulated expression implies a functional basis for production of GHBP. The wide tissue distribution of GHBP mRNA also suggests a role for GHBP as a paracrine/autocrine effector molecule, perhaps in addition to an endocrine role. Additional studies, both in vitro and in vivo, perhaps utilizing highly purified recombinant GHBP, will be required to provide more definitive information as to the true physiological role(s) of the circulating GHBPs.

Does the serum binding protein for growth hormone have a functional role?

The presence in the serum of several animal species of highly specific binding proteins for growth hormone is now accepted. The major binding protein is a truncated, variant form of the target tissue GH receptor and is synthesized by all tissues expressing the full-length GH receptor. The GH receptor and GH binding protein are not co-ordinately expressed, being produced in variable ratios between tissues. Such independence of expression suggests that the synthesis of the GH binding protein is regulated and therefore may be biologically relevant. The GH binding protein has been shown to increase the half-life of circulating GH by decreasing the metabolic clearance rate and degradation rate; to limit the volume of distribution of bound GH to approximately twice the intravascular space; and to inhibit receptor binding and biological actions of GH in in vitro model systems. These observations suggest that circulating GH binding protein does have a functional role in modulating both the circulating concentrations of GH and its availability and effectiveness for target tissue interaction. Other possible, but as yet unproven, functions for the GH binding protein are briefly discussed. The ability to produce GH binding protein by recombinant means should allow additional, more definitive studies to be performed, thereby providing greater opportunity to define the true biological role(s) of the GH binding protein in the metabolism and function of GH.

Binding sites for growth hormone in rabbit placental cytosol.

A soluble GH-binding protein, which cross-reacted with a monoclonal antibody (Mab) to the rabbit liver membrane GH receptor, has been identified in cytosol preparations from both fetal and maternal portions of rabbit placenta. Structural studies using gel filtration chromatography and chemical covalent cross-linking techniques have shown that the GH-binding protein in fetal/maternal placental cytosol has a native mol wt of 104,000 and a denatured subunit of about 57,000 mol wt (with or without dithiothreitol). Very low levels of GH-specific [125I]human (h) GH binding were observed in membrane preparations from the corresponding placentae, even after desaturation of any endogenously bound hormone by 5 M MgCl2. No PRL-specific binding was observed in placental membranes or cytosols. Scatchard analysis of [125I]hGH binding to fetal and maternal placental cytosol revealed linear plots with Ka values of 6.1 +/- 1.1 nM-1 (fetal) and 5.31 +/- 0.63 nM-1 (maternal; mean +/- SEM; n = 5). The binding capacity of maternal placental cytosol, when expressed as femtomoles per mg protein (170 +/- 10.10) or femtomoles per g tissue (3245 +/- 123), was about 3-fold higher than that for fetal placental cytosol. Northern blot analysis of fetal and maternal placental mRNA probed with a GH receptor oligonucleotide probe revealed hybridization to a 4.4 to 4.7-kilobase and a 2.2-kilobase species in fetal placenta only. The level of GH-specific binding observed in fetal and maternal placental cytosol did not correlate directly with the level of mRNA expression. A GH-binding protein has also been shown to be present in fetal rabbit serum and is known to be structurally and immunologically related to the rabbit placental and liver cytosolic GH-binding proteins. Scatchard analysis of [125I]hGH binding to fetal serum GH-binding protein revealed a single class of high affinity sites with a Ka of 4.64 +/- 1.29 nM-1 and a capacity of 338 +/- 167 fmol/ml serum (mean +/- SEM; n = 4). Given the relative binding capacities and the demonstration of GH receptor mRNA in fetal placental cytosol, it is highly unlikely that contamination of fetal placental cytosol by fetal serum accounts for all of the placental binding capacity observed. However, no such definitive conclusion regarding contamination by maternal rabbit serum of maternal placental cytosol can be made. The presence of GH-binding proteins in placental cytosol has not been described previously, and these observations suggest that GH may have a role in placental metabolism.

Differences in the developmental patterns of somatotrophic and lactogenic receptors in rabbit liver cytosol.

These studies have examined the ontogeny of specific GH- and PRL-binding proteins in rabbit liver cytosol across the fetal, early neonatal, and adult periods. The precise hormonal specificity of binding of the somatotropic/lactogenic ligand, [125I]human GH, was determined by displacement with monoclonal antibodies against either rabbit mammary gland PRL receptors or liver GH receptors. The developmental changes were evaluated by gel filtration chromatography, which allowed a measure of both the extent of binding and the molecular size (Mr). Scatchard analysis indicated that fetal liver cytosol contained mostly high affinity PRL receptors (Ka, 13.78 +/- 0.98 nM-1; capacity, 127 +/- 24.0 fmol/g tissue; mean +/- SEM; n = 5) and was low in GH-specific binding. This contrasts markedly with adult liver cytosol, which is a rich source of GH receptors (Ka, 2.44 nM-1; capacity, 20,765 fmol/g tissue), but is low in PRL-specific binding. Despite the deficiency of GH receptors in fetal liver, an abundant receptor-like GH-binding protein was present in fetal serum. Of several fetal tissue cytosols examined, only the placenta contained significant GH-specific binding; no tissues other than liver contained PRL-specific binding. After parturition PRL receptors in liver cytosol increased and predominated up until day 3 (Ka, 27.97 +/- 6.27 nM-1; capacity, 495 +/- 95.09 fmol/g tissue; n = 7), a period during which GH-specific binding was increasing only slightly. By day 6 a striking switch-over occurred, and GH receptors, which had a 4-fold lower affinity, became predominant (Ka, 6.89 +/- 0.63 nM-1; capacity, 600 +/- 47 fmol/g tissue; n = 5), while PRL-specific binding fell dramatically to levels observed in adult liver cytosol. After day 6 GH receptors increased steadily, reaching the high levels observed in adulthood by 2 months (Ka, 3.95 nM-1; capacity, 16,300 fmol/g tissue; n = 2), while PRL-specific binding appeared to change little. Structural and immunological analyses of the cytosolic GH and PRL receptors in the fetal/early neonatal period revealed similarities with the adult liver cytosolic GH receptor and mammary gland cytosolic PRL receptor, respectively. The increase in GH receptors on day 6 was clearly illustrated by cross-linking studies which showed the emergence of a GH-specific binding protein structurally distinct from PRL-specific binding proteins. These studies have demonstrated that in the rabbit major changes occur in the GH/PRL receptor profile during the early period of growth and suggest that important developmental changes occur in the requirement for GH and/or PRL action during this period.

Binding proteins for growth hormone and prolactin in rabbit kidney cytosol.

Two soluble, receptor-like binding proteins with apparent somatotrophic [growth hormone (GH)] and lactogenic [prolactin (PRL)] specificities, respectively, and that are present in rabbit kidney cytosol have now been examined in more detail using specific GH receptor and PRL receptor monoclonal antibodies (MAb). Gel chromatography of 125I-labeled human GH (125I-hGH) kidney cytosol complexes in the absence of these MAbs revealed two specifically bound regions of radioactivity at molecular weights (MW) of approximately 120,000 and approximately 60,000, which are similar in size to complexes formed by the native GH receptor of rabbit liver cytosol and the PRL receptor of mammary gland. Co-incubation with GH-receptor MAb inhibited 125I-hGH binding only to the higher MW (120,000) species, whereas the PRL-receptor MAb inhibited only the lower MW (60,000) species, thus establishing definitively the hormonal specificities of the two binding proteins. The presence of both GH- and PRL-specific binding subunits in cytosol was confirmed using covalent cross-linking techniques. No GH binding protein was detected in kidney membranes. The presence of naturally soluble, receptor-like binding proteins for GH and PRL in kidney cytosol preparations raises the possibility of their playing a role in the intracellular regulation of kidney function and/or metabolism.

Immunological relationship and binding capacity of prolactin receptors in cytosolic and membrane fractions of rabbit mammary gland.

We have recently identified and partially characterized a specific lactogen binding protein in rabbit mammary gland cytosol. In this report, studies using pregnant or lactating rabbits are described which further characterize the cytosolic lactogen binding protein in relation to the membrane-bound lactogen receptor. The data show that in pregnant or lactating rabbits the binding capacity (fmol/mg protein) of membranes is at least double that of the cytosol preparation although when expressed on a tissue content basis (fmol/g tissue) there was no membrane-cytosol difference in receptor number. Treatment of lactating rabbits with CB-154, however, caused a marked increase (100-150%) in the binding capacity of membrane-bound receptors with comparatively little effect (+20%) on the cytosolic lactogram binding protein. There was also a marked difference in the association constants for 125I-hGH, with the cytosolic lactogen binding protein exhibiting a 6-fold higher affinity than the membrane-bound receptor. Three anti-prolactin receptor monoclonal antibodies (M110, A82 (antagonists) and A917 (agonist) have also been used to assess the relative immunological characteristics of the cytosolic lactogen binding protein and the membrane lactogen receptor. Each monoclonal antibody was able to inhibit the specific binding of 125I-hGH to both membranes and cytosol in a dose-dependent manner. However, the order of potency was not identical being M110 greater than A917 greater than A82 in membranes and M110 greater than A82 greater than A917 in cytosol. A917 was at least 10 times more active in membranes than cytosol whereas A82 was at least 10 times more active in cytosol.(ABSTRACT TRUNCATED AT 250 WORDS)

Structural studies on membrane-bound and soluble growth-hormone-binding proteins of rabbit liver.

Covalent cross-linking techniques have been used to investigate the structural characteristics of the growth-hormone (GH) receptor in a variety of rabbit liver cell membrane preparations (particulate and soluble). Two classes of GH-binding protein have been identified which differ in their Mr by gel filtration and susceptibility to precipitation with poly(ethylene glycol) (PEG). The first, a PEG-precipitable (Mr approximately 300,000) protein, contained Mr-65,000 and Mr-40,000 binding proteins linked by disulphide bonds. It was present in aqueous extracts derived from microsomal membranes but was not present in cytosol preparations. The second, a PEG-non-precipitable protein (Mr approximately 100,000) was composed of a non-disulphide-linked primary GH-binding subunit of Mr 60,000-66,000. This binding protein was present in all rabbit liver cell fractions and/or preparations. Both binding-protein classes contained intramolecular disulphide bonds. It is not clear whether the Mr-approximately 100,000 form, or perhaps higher-Mr species which have not been identified by cross-linking studies, represents the native, endogenous, form of the GH receptor present in particulate microsomal or plasma membranes. Accordingly, although these data have identified two classes of GH-binding protein, especially a primary GH-binding subunit of Mr 60,000-66,000, they indicate that, unlike studies on the insulin receptor, covalent cross-linking techniques alone are not sufficient to delineate the complete subunit structure of the native and endogenous form of the GH receptor.

Binding and structural characteristics of a soluble lactogen-binding protein from rabbit mammary-gland cytosol.

Specific receptors for prolactin (PRL) are known to be present on plasma membranes and intracellular membranes of mammary gland. We now report, however, the detection and characterization of a soluble lactogen-specific binding protein in high-speed (200,000 g) cytosolic preparations from pregnant- and non-pregnant-rabbit mammary gland. The binding protein was not detectable by poly(ethylene glycol) precipitation; instead, bound and free 125I-labelled human growth hormone (hGH; a potent lactogen) was separated using a mini-gel filtration technique. Specific binding of 125I-hGH reached an apparent equilibrium between 10 and 14 h at 21-23 degrees C. It was dependent on mammary-gland protein concentration and, partially, on Ca2+ or Mg2+ concentrations. Scatchard analysis revealed steep curvilinear plots, the high-affinity component having a KA of approximately 3 X 10(10) M-1. Gel filtration on calibrated Ultrogel AcA34 columns of 125I-hGH-cytosol complexes or of cytosol alone, followed by measurement of 125I-hGH binding in each eluted fraction, indicated that the binding protein had an Mr of 33,000-43,000. A specific binding protein of the same size was observed when 125I-ovine or -human PRL, but not 125I-bovine GH, was used as ligand. The apparent lactogenic specificity was confirmed by a lack of cross-reactivity of the binding protein with an anti-[GH receptor (rabbit liver)] monoclonal antibody. Polyacrylamide-gel electrophoresis of 125I-hGH covalently cross-linked to cytosol with disuccinimidyl suberate revealed binding proteins of Mr 35,000 (non-reduced) and 37,000 (reduced), results comparable with those obtained by gel filtration and indicating an absence of inter-subunit disulphide bonds. These studies have shown the presence of an apparently naturally soluble lactogen-binding protein in the cytosolic fraction of rabbit mammary gland. The relationship between this binding protein and the membrane PRL receptor is not yet known.

Affinity purification and structural characterization of a specific binding protein for human growth hormone in human serum.

A highly specific binding protein for human growth hormone (hGH) has been isolated from human serum by hGH-affinity chromatography. A purification of approximately 1500-fold with a 30-40% recovery was obtained with essentially no alteration in binding characteristics. Covalent cross-linking of 125I-hGH to the binding protein, followed by analysis by SDS-polyacrylamide gel electrophoresis and autoradiography, revealed two specifically labeled complexes. Allowing for a 1:1 binding stoichiometry the binding proteins themselves had mean mol wts of 57,000 and 69,300. These increased slightly to mol wt 60,300 and 72,000 respectively in the presence of 100 mM dithiothreitol, suggesting the presence of intramolecular but not inter-subunit disulfide linkages. These data confirm the presence of the hGH binding protein(s) in human serum and define their gross structural nature.

Evidence for the specific binding of growth hormone to a receptor-like protein in rabbit serum.

The binding in vitro of 125I-human or bovine growth hormone (GH) to normal female rabbit serum has been studied using gel filtration to separate bound and free hormone. On Ultrogel AcA34 columns, a substantial peak of specific 125I-GH binding was observed at a MW approximately 120 000. This peak was not precipitable by 12.5% polyethylene glycol, a method used widely for solubilized hormone receptors. Assuming a 1:1 binding stoichiometry between GH (MW 21 000) and the binding protein, the MW of the binding protein would be approximately 100 000. Gel filtration of serum alone, followed by assessment of 125I-hGH binding in column fractions, indicated the binding protein had a similar MW (83 000-107 000). Specific binding of 125I-hGH was dependent on incubation time (equilibrium being reached in 2 h at 21 degrees C), Ca2+ concentration (0.5-2.0 mM) and serum concentration (a 1:5 dilution of serum giving 45.2 +/- 1.7% specific binding; mean +/- SE, n = 10). Binding was completely reversible (t 1/2 approximately 1.5 h) and specific for somatotrophic but not lactogenic hormones. Scatchard analysis revealed linear plots with a Ka 1.59 +/- 0.11 X 10(9) M-1 and capacity 3700 fmol/ml serum. The presence in rabbit serum of a high affinity, GH-specific, binding protein raises important questions regarding its identity and possible physiological role in modulating the delivery and/or activity of GH in vivo.

Identification of a rabbit liver cytosolic binding protein for human growth hormone.

A specific growth hormone (GH) binding protein of Mr approx. 100000 has been demonstrated in the cytosolic fraction (200000g supernatant) of pregnant-rabbit liver by gel filtration techniques. This binding species was detectable by a standard charcoal separation procedure but not by the widely used poly(ethylene glycol) precipitation method. The GH binding protein had similar binding characteristics to those of classical membrane-bound GH receptors. The kinetics of association and dissociation, binding affinity (2.56 X 10(9)1/mol) and hormonal specificity have been established. There appears to be equal or greater amounts of GH binding protein in the cytosol than in the membrane fraction. The presence of the GH binding protein in rabbit liver cytosol was substantiated by its selective purification on a GH-Affigel 15 affinity column. This technique has resulted in a 200-300-fold purification with no substantial change in binding affinity. The ability of a concanavalin A-Sepharose affinity column to also bind the cytosolic binding protein indicates that, like the membrane-bound GH receptor, it is a glycoprotein. This is the first report of a cytosolic binding protein for GH and raises important questions regarding its potential physiological role in the mechanism of action of GH.

Water-soluble hepatic growth hormone receptors: structural studies using gel chromatography and chemical cross-linking.

Gel filtration of a water-solubilized human GH (hGH)-binding protein from rabbit liver has indicated that the binding species as determined by polyethylene glycol precipitation, was of mol wt greater than or equal to 300,000. In contrast, gel filtration of 125I-hGH-binding protein complex revealed in addition a major binding species of mol wt approximately 100,000. This species was shown not to be detectable by polyethylene glycol precipitation. Further, this same binding protein was observed after incubation with 125I-bovine GH but not 125I-ovine PRL, suggesting that it was specific for the somatotrophic but not lactogenic receptor of pregnant rabbit liver. Covalent cross-linking studies using disuccinimidyl suberate and sodium dodecyl sulfate gel electrophoresis, under reducing and nonreducing conditions, revealed a predominant binding subunit of mol wt 57,000, as well as smaller amounts of a mol wt 124,000 species. These data indicate that the structure of the binding protein involves no intersubunit disulfide bonds and suggest that the primary hGH binding subunit of pregnant rabbit liver has a mol wt of 57,000 and exists naturally as a dimer (mol wt, 100-124,000) and perhaps larger oligomers of mol wt greater than or equal to 300,000.